These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30997685)

  • 1. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints.
    Sofeu CL; Emura T; Rondeau V
    Stat Med; 2019 Jul; 38(16):2928-2942. PubMed ID: 30997685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
    Sofeu CL; Emura T; Rondeau V
    Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
    Sofeu CL; Rondeau V
    PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
    Rotolo F; Paoletti X; Michiels S
    Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials.
    Emura T; Sofeu CL; Rondeau V
    Stat Methods Med Res; 2021 Dec; 30(12):2634-2650. PubMed ID: 34632882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error.
    Belhechmi S; Michiels S; Paoletti X; Rotolo F
    Contemp Clin Trials Commun; 2019 Sep; 15():100402. PubMed ID: 31338479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.
    Rotolo F; Paoletti X; Burzykowski T; Buyse M; Michiels S
    Stat Methods Med Res; 2019 Jan; 28(1):170-183. PubMed ID: 28681681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reflection on the causal interpretation of individual-level surrogacy.
    Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
    J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate endpoint evaluation using data from one large global randomized controlled trial.
    Geybels M; Wolthers BO; Kreiner FF; Rasmussen S; Bauer R
    BMC Med Inform Decis Mak; 2021 May; 21(1):164. PubMed ID: 34016120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
    Banerjee B; Biswas A
    J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
    Molenberghs G; Buyse M; Geys H; Renard D; Burzykowski T; Alonso A
    Control Clin Trials; 2002 Dec; 23(6):607-25. PubMed ID: 12505240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.
    Ghosh D; Taylor JM; Sargent DJ
    Biometrics; 2012 Mar; 68(1):226-32. PubMed ID: 21668903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
    Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
    Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate endpoints in randomized cardiovascular clinical trials.
    Domanski M; Pocock S; Bernaud C; Borer J; Geller N; Revkin J; Zannad F
    Fundam Clin Pharmacol; 2011 Aug; 25(4):411-3. PubMed ID: 20698890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate end points for overall survival in breast cancer trials: A review.
    Fiteni F; Bonnetain F
    Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.